Citation Impact
Citing Papers
CD73 Is Associated with Poor Prognosis in High-Grade Serous Ovarian Cancer
2015
Anti-CTLA-4 Immunotherapy Does Not Deplete FOXP3+ Regulatory T Cells (Tregs) in Human Cancers
2018 StandoutNobel
Targeting CD73 Enhances the Antitumor Activity of Anti-PD-1 and Anti-CTLA-4 mAbs
2013
The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4
2015
Sialic Acid Blockade Suppresses Tumor Growth by Enhancing T-cell–Mediated Tumor Immunity
2018
Myeloid Expression of Adenosine A2A Receptor Suppresses T and NK Cell Responses in the Solid Tumor Microenvironment
2014
CD73-Deficient Mice Are Resistant to Carcinogenesis
2012
CD73-Deficient Mice Have Increased Antitumor Immunity and Are Resistant to Experimental Metastasis
2011
Cancer Exosomes Express CD39 and CD73, Which Suppress T Cells through Adenosine Production
2011
The Role of Neoantigens in Naturally Occurring and Therapeutically Induced Immune Responses to Cancer
2016
Chimeric NKG2D Expressing T Cells Eliminate Immunosuppression and Activate Immunity within the Ovarian Tumor Microenvironment
2009
Targeted glycan degradation potentiates the anticancer immune response in vivo
2020 StandoutNobel
Different subsets of tumor infiltrating lymphocytes correlate with NPC progression in different ways
2010
CRISPR/Cas9 mediated deletion of the adenosine A2A receptor enhances CAR T cell efficacy
2021
A Novel Antagonist of the Immune Checkpoint Protein Adenosine A2a Receptor Restores Tumor-Infiltrating Lymphocyte Activity in the Context of the Tumor Microenvironment
2017
Myeloid-derived suppressor cells coming of age
2018 Standout
Elements of cancer immunity and the cancer–immune set point
2017 StandoutNature
Anti-CD73 in Cancer Immunotherapy: Awakening New Opportunities
2016
Characterization and inhibition of a p38-like mitogen-activated protein kinase (MAPK) from Echinococcus multilocularis: Antiparasitic activities of p38 MAPK inhibitors
2008
MDSCs: Key Criminals of Tumor Pre-metastatic Niche Formation
2019
Cellular function and molecular structure of ecto-nucleotidases
2012
Targeting immunosuppressive adenosine in cancer
2017
Nucleotide signalling during inflammation
2014 StandoutNature
Extracellular adenosine triphosphate and adenosine in cancer
2010
Innate and adaptive immune cells in the tumor microenvironment
2013 Standout
Approaches to treat immune hot, altered and cold tumours with combination immunotherapies
2019 Standout
Regulatory T Cells
2010
Enhancement of tumor immunotherapy by deletion of the A2A adenosine receptor
2011
Bioorthogonal labeling cell-surface proteins expressed in pancreatic cancer cells to identify potential diagnostic/therapeutic biomarkers
2015
Cancer drug resistance: an evolving paradigm
2013 Standout
Myeloid-derived suppressor cells in the era of increasing myeloid cell diversity
2021 Standout
Understanding the tumor immune microenvironment (TIME) for effective therapy
2018 Standout
Systemic oxygenation weakens the hypoxia and hypoxia inducible factor 1α-dependent and extracellular adenosine-mediated tumor protection
2014
Graft-versus-Host Disease Is Enhanced by Selective CD73 Blockade in Mice
2013
Hypoxia-Inducible Factors: Master Regulators of Cancer Progression
2016 StandoutNobel
CRISPR-Cas9 screens identify regulators of antibody–drug conjugate toxicity
2019 StandoutNobel
The immune contexture in cancer prognosis and treatment
2017 Standout
CD73: a potent suppressor of antitumor immune responses
2012
Interaction between microbiota and immunity in health and disease
2020 Standout
Inflammation and tumor progression: signaling pathways and targeted intervention
2021 Standout
Pericytes: Developmental, Physiological, and Pathological Perspectives, Problems, and Promises
2011 Standout
Bioengineering Strategies for Designing Targeted Cancer Therapies
2013
Ectonucleotidases CD39 and CD73 on OvCA cells are potent adenosine-generating enzymes responsible for adenosine receptor 2A-dependent suppression of T cell function and NK cell cytotoxicity
2011
Targeting the hypoxia-adenosinergic signaling pathway to improve the adoptive immunotherapy of cancer
2013
IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumors in vivo
2015
Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function
2019
The intestinal microbiota fuelling metabolic inflammation
2019
Regulation and Function of the PD-L1 Checkpoint
2018 Standout
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
2017 Standout
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
2023 Standout
Immune microenvironments in solid tumors: new targets for therapy
2011
Cancer immunotherapy comes of age
2011 StandoutNature
Crystal Structure of the Human Ecto-5′-Nucleotidase (CD73): Insights into the Regulation of Purinergic Signaling
2012
Immunosuppressive activities of adenosine in cancer
2016
The immune contexture in human tumours: impact on clinical outcome
2012 Standout
The blockade of immune checkpoints in cancer immunotherapy
2012 Standout
Combination cancer immunotherapies tailored to the tumour microenvironment
2015
How the ageing microenvironment influences tumour progression
2019
Extracellular Adenosine-Mediated Modulation of Regulatory T Cells
2014
Classification, Functions, and Clinical Relevance of Extracellular Vesicles
2012 Standout
Adenosine receptors as drug targets — what are the challenges?
2013
Caffeine promotes anti-tumor immune response during tumor initiation: Involvement of the adenosine A2A receptor
2015
Comparison of efficacy of immune checkpoint inhibitors (ICIs) between younger and older patients: A systematic review and meta-analysis
2016
Immune escape to PD-L1/PD-1 blockade: seven steps to success (or failure)
2016
Cornerstones of CRISPR–Cas in drug discovery and therapy
2016 StandoutNobel
Immunity, inflammation and cancer: a leading role for adenosine
2013
Microenvironmental regulation of tumor progression and metastasis
2013 Standout
Beyond the Antigen Receptor: Editing the Genome of T-Cells for Cancer Adoptive Cellular Therapies
2013
A guide to cancer immunotherapy: from T cell basic science to clinical practice
2020 Standout
Metabolic adaptation of cancer and immune cells mediated by hypoxia-inducible factors
2018 StandoutNobel
The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment
2016 Standout
NF-κB, inflammation, immunity and cancer: coming of age
2018 Standout
Immunogenic cell death and DAMPs in cancer therapy
2012 Standout
Tumor-infiltrating regulatory T cells as targets of cancer immunotherapy
2023 StandoutNobel
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
2018 Standout
Exosomes
2019 Standout
Protein kinase A–dependent phosphorylation stimulates the transcriptional activity of hypoxia-inducible factor 1
2016 StandoutNobel
Echinococcosis: Advances in the 21st Century
2019 Standout
Immunological mechanisms of the antitumor effects of supplemental oxygenation
2015
Chromone: A Valid Scaffold in Medicinal Chemistry
2014 Standout
Immune-Related Adverse Events Associated with Immune Checkpoint Blockade
2018 Standout
ICOS+Foxp3+TILs in gastric cancer are prognostic markers and effector regulatory T cells associated withHelicobacter pylori
2016 StandoutNobel
Hypoxia-inducible factor 1-dependent expression of adenosine receptor 2B promotes breast cancer stem cell enrichment
2018 StandoutNobel
Anti-CD39 and anti-CD73 antibodies A1 and 7G2 improve targeted therapy in ovarian cancer by blocking adenosine-dependent immune evasion.
2014
Oxygen Sensing, Hypoxia-Inducible Factors, and Disease Pathophysiology
2013 StandoutNobel
PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: Mechanisms, response biomarkers, and combinations
2016 Standout
Transcriptional regulation of myeloid-derived suppressor cells
2015
Chemotherapy induces enrichment of CD47 + /CD73 + /PDL1 + immune evasive triple-negative breast cancer cells
2018 StandoutNobel
Blockade of A 2A receptors potently suppresses the metastasis of CD73 + tumors
2013
Role of adenosine in tumor progression: focus on A2B receptor as potential therapeutic target
2017
The biology , function , and biomedical applications of exosomes
2020 StandoutScience
The ectonucleotidases CD 39 and CD 73: Novel checkpoint inhibitor targets
2017
Adenosinergic Regulation of the Expansion and Immunosuppressive Activity of CD11b+Gr1+ Cells
2011
Identification of a pharmacologically tractable Fra-1/ADORA2B axis promoting breast cancer metastasis
2013
Anti‐CD73 therapy impairs tumor angiogenesis
2013
Esterase- and pH-responsive poly(β-amino ester)-capped mesoporous silica nanoparticles for drug delivery
2015 StandoutNobel
A Metabolic Immune Checkpoint: Adenosine in Tumor Microenvironment
2016
HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells
2015 StandoutNobel
Antimetastatic Effects of Blocking PD-1 and the Adenosine A2A Receptor
2014
Ionizable Lipid Nanoparticles with Integrated Immune Checkpoint Inhibition for mRNA CAR T Cell Engineering
2023 StandoutNobel
Immunogenic Cell Death in Cancer Therapy
2012 Standout
Chemical Glycoproteomics
2016 StandoutNobel
Hyper-Progressive Disease: The Potential Role and Consequences of T-Regulatory Cells Foiling Anti-PD-1 Cancer Immunotherapy
2020 StandoutNobel
IL-2 therapy promotes suppressive ICOS+ Treg expansion in melanoma patients
2013
Works of Benjamin J. Daniel being referenced
Mitigating Age-Related Immune Dysfunction Heightens the Efficacy of Tumor Immunotherapy in Aged Mice
2012
CD73 on Tumor Cells Impairs Antitumor T-Cell Responses: A Novel Mechanism of Tumor-Induced Immune Suppression
2010
A low dose lipid infusion is sufficient to induce insulin resistance and a pro-inflammatory response in human subjects
2018
Trends in immunoconjugate and ligand-receptor based targeting development for cancer therapy
2007
Manipulating T regulatory cells in cancer immunotherapy
2006
Drugs Designed To Inhibit Human p38 Mitogen-Activated Protein Kinase Activation TreatToxoplasma gondiiandEncephalitozoon cuniculiInfection
2007
Regulatory T Cells: A New Frontier in Cancer Immunotherapy
2008